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Abstract
Background: Normal urothelium is characterised by terminally differentiated superficial cells,
which express cytokeratin 20 in the cytoplasm. In contrast, cultured human stratified urothelium,
which does not undergo complete terminal differentiation of its superficial cells, does not express
cytokeratin 20. If spinal cord injury (SCI) affects urothelial differentiation or induces squamous or
other metaplastic change undetected by histological analysis, the superficial urothelial cells of the
neuropathic bladder might be expected to show absence of immunostaining for cytokeratin 20.
Patients and Methods: We studied immunostaining for cytokeratin 20 in bladder biopsies taken
from 63 consecutive SCI patients. Immunostaining was performed on paraffin-embedded tissue
using a mouse monoclonal antibody (clone: Ks20.8).
Results: Of 63 biopsies, the epithelium was scarce in two. Eight biopsies showed squamous
metaplasia and immunostaining for cytokeratin 20 was absent in all the eight biopsies. Of the
remaining 53 cases, in which the umbrella cell layer of the urothelium was intact, immunostaining
for cytokeratin 20 was seen only in ten biopsies.
Conclusion: Superficial cells in the transitional epithelium showed immunostaining for cytokeratin
20 in 10 of 53 bladder biopsies taken from SCI patients. The reasons for this could be either that
there is an underlying metaplasia or that changes in the neuropathic bladder affect urothelial
differentiation. Taken with evidence from other systems, such as loss of cytokeratin 20 expression
from static organ cultures of urothelial tissue, this might suggest that other factors, such as
impairment of voluntary voiding in SCI patients, could affect expression of markers such as
cytokeratin 20.
Introduction
Normal urothelium serves as the main source of a major
class of soluble, urine proteins including urokinase, tis-
sue-type plasminogen activator, and a potent serine pro-
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tease inhibitor, PP5 [1]; their synthesis requires
differentiation of the vesical urothelium. It is speculated
that these urinary proteins and their inhibitors play a cru-
cial role in regulating desquamation of urothelium, which
constitutes a vital defence mechanism against bacterial at-
tachment. Thus the mammalian urothelium, besides act-
ing as a permeability barrier, may serve important
functions in prevention of bacterial cystitis.
Urothelium is characterised by terminally differentiated
superficial cells ("umbrella cells"), that express uroplakins
in their luminal plasma membrane and cytokeratin 20 in
their cytoplasm. Basal and intermediate cells are cytoker-
atin 20 negative. [2] In contrast to normal urothelium,
cultured human stratified urothelium does not undergo
complete terminal differentiation of its superficial cells.
Using immunohistochemical staining with specific anti-
bodies, the superficial layer of reconstructed stratified
urothelium has been shown to express uroplakins but not
cytokeratin 20 [3–5].
We studied cytokeratin-20 immunostaining of bladder bi-
opsies taken from spinal cord injury patients. It is possible
that injury to the spinal cord, and consequent lack of
trophic effect upon the urothelium, may lead to incom-
plete maturation and differentiation. [6]. As normal
urothelium is characterised by cytoplasmic cytokeratin 20
expression in terminally differentiated superficial cells, cy-
tokeratin 20 was taken as a marker of complete terminal
differentiation of urothelial cells in bladder biopsies. If
spinal cord injury does indeed affect urothelial differenti-
ation or induces squamous or other metaplastic change
undetected by histological analysis, the superficial urothe-
lial cells in the neuropathic bladder of SCI patients may
not show positive immunostaining for cytokeratin 20.
Patients and Methods
Bladder biopsies were obtained from 63 spinal cord injury
patients after obtaining written informed consent. The
North Sefton Local Research Ethics Committee approved
this study. All were adults with spinal cord injury and neu-
ropathic bladder. They were registered with the Regional
Spinal Injuries Centre, Southport, England; were not suf-
fering from acute urinary infection and were undergoing
an elective therapeutic procedure in the urinary tract such
as endoscopic lithotripsy of bladder stone, insertion of a
ureteric stent, or diagnostic cystoscopy.
Figure 1
Bladder biopsy from a male with ventilator-dependent tetraplegia (DC) shows no immunostaining for cytokeratin 20.BMC Urology 2002, 2 http://www.biomedcentral.com/1471-2490/2/7
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After routine prophylactic intravenous gentamicin, cold
cup biopsies of the bladder mucosa were taken from the
trigone of the urinary bladder. Thereafter, the biopsy site
was fulgurated with diathermy to achieve haemostasis. In-
dwelling urinary catheter drainage was maintained after
the procedure, and all patients remained in hospital for at
least 24 hours. Biopsies were fixed in neutral buffered for-
maldehyde 4%, and then embedded in Paraplast. (Para-
plast is a commercial paraffin wax incorporating
plasticisers, used for embedding formalin-fixed tissues for
histology.)
A Consultant Cellular Pathologist recorded the his-
topathological features of each bladder biopsy after exam-
ining sections stained with haematoxylin and eosin. None
of the 63 biopsies from spinal cord injury patients showed
evidence of dysplasia or neoplasia. The classical morpho-
logical features of dysplasia in the urothelium comprise:
increased nucleo-cytoplasmic ratio, nuclear hyperchro-
matism, abnormal chromatin pattern, prominent nucleo-
li, and nuclear pleomorphism; and loss of normal polarity
leading to a haphazard spatial arrangement of urothelial
cells. The affected urothelium is, by definition, flat rather
than papillary. In the most severe form of dysplasia (car-
cinoma-in-situ), the above nuclear characteristics are
present to a marked degree, comparable in severity to
those in a grade 3 Transitional Cell Carcinoma. Lesser de-
grees are termed 'dysplasia not amounting to carcinoma-
in-situ'. At the mild end of the spectrum, distinguishing
dysplasia from inflammatory or regenerative atypia can be
difficult; the abnormal chromatin pattern in dysplasia is
usually the most reliable criterion.
In two biopsies, epithelium was scarce. Eight biopsies
showed squamous metaplasia with no transitional epithe-
lium present. Umbrella cells were identifiable in the re-
maining 53 biopsies at least in one microscopic field.
Umbrella cells were identified by their morphological
characteristics, namely: large, elongated cells with abun-
dant eosinophilic cytoplasm, their long axes parallel to
the basement membrane, covering several underlying in-
termediate urothelial cells. The umbrella cells may occa-
sionally be binucleate.
Immunostaining for cytokeratin 20 was carried out on tis-
sue sections in one lot using a mouse monoclonal anti-
body, clone Ks20.8 (Novocastra Laboratories Ltd, Balliol
Business Park West, Benton Lane, Newcastle upon Tyne
NE12 8EW, UK). This is an IgG antibody (IgG2a, kappa),
with specificity for human cytokeratin 20 intermediate fil-
ament protein, raised against cytoskeletal preparations
isolated from microdissected villi of human duodenal
Figure 2
Bladder biopsy from a male with L-2 paraplegia (MW-37): Immunostaining for cytokeratin 20 shows positive staining in
umbrella cells.BMC Urology 2002, 2 http://www.biomedcentral.com/1471-2490/2/7
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mucosa. The normal positive staining pattern for cytoker-
atin 20 is cytoplasmic. The manufacturer's instructions
were followed for immuno-staining. Sections were pre-
treated with proteinase-K, to unmask cytokeratin epitopes
masked by the cross-linking effect of formaldehyde during
fixation and tissue processing. The antibody was used at a
working dilution of 1:25. Immunoperoxidase technique
was employed, with primary antibody incubation at 25°C
for 60 minutes. Each sample included a negative control,
by omitting the primary antibody. Avidin Biotin Complex
(ABC) kit was purchased from Vector Laboratories. The
version of the kit used was Elite ABC.
The presence of immunostaining in the vesical epithelium
was recorded either as negative or positive, and the loca-
tion of any positively staining cells within the transitional
epithelium was noted.
Results
Vesical urothelium in the patients with SCI showed no
immunostaining for cytokeratin 20 in 43 of 53 cases, in
which transitional epithelium was identifiable (Figure 1).
Haematoxylin and eosin sections showed clearly identifi-
able umbrella cells in these biopsies, thereby excluding
false-negative staining due to mechanical denudation of
the epithelium. Positive immunostaining for cytokeratin
20 was observed in only ten biopsies (Table 1). Immunos-
taining was limited to occasional cells in the superficial
layer of urothelium (Figures 2 and 3). Immunostaining
for CK-20 was absent in all eight biopsies, which showed
squamous metaplasia.
Figure 3
Bladder biopsy from a male with C-7 tetraplegia (HW-44): Immunostaining for cytokeratin 20 shows a few faintly positive cells
in the superficial layer of urothelium.BMC Urology 2002, 2 http://www.biomedcentral.com/1471-2490/2/7
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Discussion
In an earlier study, we observed strong immunostaining
for secretory immunoglobulin A (sIgA) in the urothelium
of all biopsies taken from non-neuropathic bladders, but
in only 18 of 37 biopsies from neuropathic bladders. [7].
This suggested that interruption of the nerve supply to the
urinary bladder might be associated with alterations in
urothelial differentiation and maturation. In the present
study, we observed positive staining for cytokeratin 20, a
marker of terminal urothelial differentiation, in only 10
of 53 biopsies taken from spinal cord injury patients,
thereby providing further supporting evidence to that hy-
pothesis.
Harnden and associates [8] noted positive immunostain-
ing for cytokeratin 20 in the umbrella cells of all control
biopsies, with staining restricted to the umbrella cells in
24 of 30 biopsies; in the remaining six cases, occasional
dispersed intermediate cells also stained positively. Basal
cells were consistently negative. A similar pattern of im-
munostaining was observed in the presence of hyperpla-
sia and inflammation. In this study, immunostaining for
cytokeratin 20 was absent in 43 of 53 biopsies taken from
the neuropathic bladders of SCI patients. This absence of
cytokeratin 20 immunostaining raises the question as to
whether the transitional epithelium of the neuropathic
bladder in SCI patients does not achieve complete func-
tional differentiation, despite apparently complete mor-
phological differentiation as judged by the presence of
umbrella cells. Terminal differentiation of the urothelium
plays a crucial role in desquamation of urothelium and
hence in prevention of bacterial cystitis; "defective" or "in-
complete" differentiation of bladder urothelium may ex-
plain why some SCI patients are at greater risk of
developing bacterial cystitis.
There appears to be an absence of cytokeratin 20 in a high
proportion of urothelium from neuropathic bladders. The
reasons for this could be either that there is an underlying
metaplasia or that changes in the neuropathic bladder af-
fect urothelial differentiation. This question could be ad-
dressed by further analysis of other differentiation
markers of urothelium, including cytokeratins and uro-
plakins. Taken with evidence from other systems, such as
loss of cytokeratin 20 expression from static organ cul-
tures of urothelial tissue [3], this might suggest that other
factors, such as impairment of normal voiding function in
SCI patients, could affect expression of differentiation
markers such as cytokeratin 20.
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Table 1: Clinical details and histopathology findings of spinal cord injury (SCI) patients in whom bladder biopsies showed positive im-
munostaining for cytokeratin-20 (CK-20)
Immuno 
Number
Age Year 
of SCI
Level of SCI 
C: Cervical T: 
Thoracic L: 
Lumbar
Method of bladder 
drainage
Histology Distribution of CK-20 
Immuno-staining
14 34 1998 C-5 Indwelling urethral catheter Moderate active chronic inflam-
mation
Few umbrella cells
16 43 1975 C-6 Indwelling urethral catheter Moderate non-specific chronic 
inflammation. Focal cystitis glan-
dularis
Individual umbrella cells and 
intestinal metaplasia.
21 58 1998 T-7 Indwelling urethral catheter Moderate chronic inflammation Individual cells in transitional 
epithelium
23 64 1959 L-1 Clam cystoplasty Intermittent 
catheterisation
Moderate acute and chronic 
inflammation. Follicular cystitis
Few umbrella cells
30 44 1989 T-12 Indwelling urethral catheter Moderate acute and chronic 
inflammation. Cystitis glandularis
Isolated cells in the superficial 
layer of transitional epithelium
37 23 1997 L-2 Intermittent catheterisation 
Haematuria
Patchy chronic inflammation. 
Patchy cystitis glandularis
Occasional umbrella cells.
44 70 1999 C-7 Indwelling urethral catheter Moderate acute and chronic 
inflammation. Follicular cystitis
Individual umbrella cells
45 22 1996 C-6 Indwelling urethral catheter Marked acute and chronic 
inflammation
Individual umbrella cells
53 23 1998 C-4 Indwelling urethral catheter Severe acute and chronic inflam-
mation. Follicular cystitis
Very few umbrella cells
6428/99 65 1991 C-4 Indwelling urethral catheter Moderate active chronic inflam-
mation. Papillary cystitis
Individual cells in transitional 
epitheliumBMC Urology 2002, 2 http://www.biomedcentral.com/1471-2490/2/7
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